An Artificial Intelligence-Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial

• Published in: The Journal of urology Vol. 213; no. 5; pp. 600 - 608
• Main Authors: Li, Eric V., Ren, Yi, Griffin, Jacqueline, Han, Jialin, Yamashita, Rikiya, Mitani, Akinori, Zhou, Ruoji, Huang, Huei-Chung, Yang, Ximing, Feng, Felix Y., Esteva, Andre, Patel, Hiten D., Schaeffer, Edward M., Cooper, Lee A. D., Ross, Ashley E.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Wolters Kluwer 01.05.2025
• Subjects: Aged; Artificial Intelligence; Humans; Male; Middle Aged; Prognosis; Prostatectomy - methods; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Survival Rate; prognosis; artificial intelligence; prostatic neoplasms
• ISSN: 0022-5347; 1527-3792; 1527-3792
• DOI: 10.1097/JU.0000000000004435

Purpose:Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer-specific mortality (PCSM) and overall survival (OS) among patients undergoing RP with digitized RP specimens.Materials and Methods:The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Randomized Controlled Trial randomized subjects from 1993 to 2001 to cancer screening or control. A subset of patients who underwent RP with available digitized histopathological images and subsequent survival data were identified. Distant metastasis (DM) and PCSM MMAIs originally trained on biopsy slides for patients undergoing radiation were evaluated for prediction of PCSM and OS. Cox proportional hazards modeling and Kaplan-Meier survival curve analysis were used.Results:In total, 1032 patients who underwent RP with median follow-up of 17 years (IQR, 14.3, 19.3 years) were identified. MMAI algorithms for PCSM and DM both predicted PCSM (HR, 2.31, 95% CI, 1.6-3.35, P < .001 and HR, 1.96, 95% CI, 1.35-2.85, P < .001, respectively). Similarly, DM and PCSM MMAI predicted OS (HR, 1.22, 95% CI, 1.01-1.47, P = .04 and HR, 1.19, 95% CI, 1.02-1.4, P = .03).Conclusions:Locked MMAI algorithms previously developed and validated on biopsy specimens from patients undergoing radiation for prostate cancer successfully predicted clinical outcomes when applied to RP specimens from patients treated with surgery. MMAI models and other biomarkers may help select patients who may benefit from postoperative treatment intensification with androgen deprivation therapy or radiation.